Background
Colitis is an inflammation of the colon. It may be associated with enteritis (inflammation of the intestine), proctitis (inflammation of the rectum), or both. Inflammatory bowel disease (IBD) is a generic term used to describe 2 idiopathic disorders that are associated with gastrointestinal (GI) inflammation:
A study from Scotland reported a 3-fold rise in newly diagnosed CD from 1968 to 1983 and a 4.4-fold rise from 1968 to 1988. However, a consistent upward trend in cases of UC in the same period did not occur.
In addition, there are a number of different conditions that can cause colitis, each of which has its own pathophysiology. These include the following:
- Allergic colitis
- Pseudomembranous colitis
- Infectious colitis (bacterial, parasitic, or viral)
- Ischemic colitis
Pathophysiology
Necrotizing enterocolitis
NEC is a common cause of colitis in newborns (see the image below). Very small and ill preterm infants are particularly susceptible to NEC. Prematurity and the presence of bacteria in the GI tract are significant risk factors associated with NEC.
Necrotizing enterocolitis totalis. NEC appears to involve a final common pathway that includes the endogenous production of inflammatory mediators, such as endotoxin lipopolysaccharide, platelet-activating factor, tumor necrosis factor, and other cytokines[1] that are involved in intestinal injury.
Hypoxic ischemia and aggressive enteral feedings are also associated with the pathogenesis of NEC. Varying degrees of mucosal or transmural necrosis of the intestine and colon are recognized. The distal ileum and proximal colon are most frequently involved; in severe cases, gangrene may involve the whole bowel from the rectum to the stomach.
NEC presents with the gas accumulation in the submucosa of the bowel wall and progresses to necrosis leading to perforation of the bowel, peritonitis, and sepsis. Histological changes in NEC include mucosal edema, hemorrhage, coagulation necrosis, and mucosal ulceration.
Allergic colitis
In children aged 2 weeks to 1 year, the most common form of colitis is allergic colitis, which results from hypersensitivity, commonly to cow’s milk and soy milk. So-called breast milk allergy is a status of food allergy induced in breastfed babies by heterologous proteins (typically cow’s milk proteins) ingested by their mothers and appearing in their breast milk. Immunologic responses may range from classic allergic mast cell activation to immune complex formation.
Pseudomembranous colitis
Pseudomembranous colitis is a form of inflammatory colitis characterized by the pathologic presence of pseudomembranes consisting of mucin, fibrin, necrotic cells, and polymorphonuclear leukocytes (PMNs).
This form of colitis is pathognomonic of infection by toxin-producing Clostridium difficile and develops as a result of altered normal microflora (usually by antibiotic therapy) that favors overgrowth and colonization of the intestine by Clostridium difficile and production of its toxins. Although every antibiotic has been reported to be associated with pseudomembranous colitis, clindamycin and amoxicillin are the antibiotics most frequently implicated in children.
Inflammatory bowel disease
IBD is an uncommon cause of chronic colitis in children (see the image below) but is becoming more frequent. The etiology is poorly understood. Genetic and environmental influences are involved in the pathogenesis. IBD may present either as UC or as CD.
Inflammatory bowel disease. Severe colitis noted during colonoscopy. The mucosa is grossly denuded, with active bleeding noted. This patient had her colon resected very shortly after this view was obtained. UC is characterized by inflammation and ulceration confined to colonic mucosa, whereas CD is manifested by transmural inflammation and granulomas that may affect any segment of the GI tract, including the colon. UC invariably involves the rectum and extends proximally without skipping segments. In contrast, CD has discontinuous patchy involvement of the GI tract, involving the small bowel, ileum, and colon.
Growth failure results from malabsorption and loss of proteins from inflammation and damage to the mucosa; it is 3 times more likely to occur in children with CD than in children with UC.
The diarrhea also results from mucosal damage, bile acid malabsorption, bacterial overgrowth, and protein exudation from mucosa. Extraintestinal manifestations, which are slightly more common in CD than in UC, result from bacterial products and inflammatory mediators (eg, cytokines, prostaglandins, and reactive oxygen metabolites) entering and subsequently being deposited in various tissues and organs, such as the eyes (uveitis), skin (erythema nodosum), liver (cholangitis, hepatitis), and joints (arthritis).
Infectious colitis
Infectious colitis is the most common cause of pediatric colitis, particularly beyond the first year of life. It can be caused by bacterial, viral, and parasitic agents.
Bacterial colitis
The most common bacterial causes of colitis in children are Escherichia coli (including both enterohemorrhagic E coli [EHEC] and enteroinvasive E coli [EIEC]) and species of Shigella, Salmonella, Campylobacter, and Yersinia.
Salmonella infections are typically spread via the fecal-oral route; outbreaks commonly are associated with contaminated eggs, dairy products, and meats. Gastric acid is usually lethal to the organism, but susceptibility to infection is increased with decreased GI motility, rapid emptying of the stomach after gastrectomy, a large quantity of ingested bacteria, malnutrition, antibiotic use, and achlorhydria.
Salmonellae can penetrate the epithelial layer to the level of the lamina propria and evoke a leukocyte response. They cause diarrhea by producing several toxins and prostaglandins, which stimulate the active secretion of fluids and electrolytes.
Shigella species attach to binding sites on the surface of the intestinal mucosal cells. The organism penetrates and proliferates in the cell, which leads to cell destruction, produces mucosal ulcerations, and causes bleeding. Shigellae also elaborate the exotoxins that produce diarrhea.
E coli may produce diarrhea in several different ways, depending on their specific pathologic characteristics. Pathologic strains of E coli have been classified as follows:
- Enteropathogenic
- Enterotoxic
- Enteroinvasive
- Enteroaggregative
- Enteroadherent
- Enterohemorrhagic
EHEC, including O157:H7 and O26:H11, causes hemorrhagic colitis and systemic complications (eg, hemolytic uremic syndrome [HUS]). The risk of developing HUS after infection with E coli O157 is estimated to be 10-15% in children. In typical infectious colitis, the lamina propria of the large intestine is infiltrated by PMNs. EIEC, on the other hand, exhibits almost exactly the same pathogenetic mechanisms as Shigella.
Parasitic colitis
Entamoeba histolytica is the most common cause of parasitic colitis in the world. Transmission takes place through ingestion of trophozoites (usually from water contamination) and person-to-person transmission (typically because of poor sanitation). Balantidium coli is a large ciliated protozoan that also causes colitis; balantidiasis manifests in much the same way as amebiasis.
Viral colitis
Colitis caused by cytomegalovirus (CMV) infection is a rare form that typically is found in immunocompromised patients (eg, organ recipients who are receiving immunosuppressive treatment). It results in deep round ulcerations that have a tendency to bleed easily and profusely.
Ischemic colitis
Ischemic colitis is a form of vasculitis that results from inflammation and ischemia of colonic mucosa, which causes rectal bleeding and abdominal pain. This form of colitis is common in Henoch-Schönlein purpura (HSP), which is considered one of the collagen vascular diseases.
Etiology
Inflammation of the colon can be caused by infection, hypersensitivity to various allergens, ischemia, vasculitis, or several drugs.
The cause of colitis in IBD is unknown, but studies have identified a gene (NOD2) that is involved in at least 20% of cases of CD. This gene is involved in the regulation of the epithelial response to bacterial antigens; this involvement underscores the role of bacteria in the pathogenesis of IBD.
There is evidence to suggest a genetic predisposition to IBD, including ethnic differences, family aggregation, concordance rates in twins, chromosomal linkage, and genetic syndromes associated with IBD. However, the lack of total concordance of disease among monozygotic twins, along with other differences, supports a role for cofactors in the development of IBD.
In the United States, bacterial and viral infections are very common causes of colitis, whereas in developing countries, parasitic infections are very common causes.
Epidemiology
United States statistics
The onset of IBD commonly occurs during adolescence and young adulthood.[2] The risk of IBD in family members of an affected individual is 7-22%; a child’s risk of acquiring the disease is more than 35% if both parents have the disease.
The prevalence of UC in the United States is 100-200 per 100,000 population. The incidence of CD is approximately 3-4 per 100,000 population, and the prevalence is 30-100 per 100,000 population. NEC affects 1-5% of patients admitting to neonatal intensive care units (ICUs). NEC may occur in 2-5% of infants with birth weights lower than 1500 g. In the United States, the prevalence of amebiasis in high-risk groups is reported to be 1-4%.
International statistics
The incidence of UC is highest in northern European countries and the United States (15/100,000) and lowest in Japan and South Africa (1/100,000).[3] A north-to-south gradient appears to be present, with higher incidences of both UC and CD in northern locations. The prevalence of amebic infections worldwide varies from 5-81%, with the highest frequencies occurring in tropical climates.
Age-, sex-, and race-related demographics
NEC is a disease of newborns, with low- and very low–birth-weight preterm infants being particularly susceptible. Allergic colitis is the most common form of colitis during the first year of life. IBD is generally diagnosed in children aged 5-16 years. It has a bimodal distribution, with an early onset at age 15-25 years and a second smaller peak at age 50-80 years. HSP occurs in school-aged children and young adults.[4] It is common in males.
The prevalence of IBD is increased among Jewish people of European Ashkenazi descent. A positive family history is the most consistent risk factor for children with IBD. HSP is common in white people. Food-allergic colitis is believed to be present in approximately 0.5% of all infants.
Prognosis
Diarrheal diseases are among the leading causes of morbidity and mortality in children worldwide, causing 1 billion episodes of illness and 3-5 million deaths annually. In the United States, 20-35 million episodes of diarrhea occur each year in the 16.5 million children who are younger than 5 years, resulting in 300-400 deaths.
Medical treatment fails in 20% of patients who have NEC with pneumatosis intestinalis at diagnosis, resulting in a 9-25% mortality. The mortality of NEC is higher than 50% in infants with birth weights lower than 1000 g.
About 70% children with UC enter remission within 3 months of initial therapy, and 50% remain in remission over the next year. Colectomy within 5 years is required in as many as 26% of children who present with severe disease compared with less than 10% of those who present with mild disease. Approximately 70% of children with CD require surgery within 10-20 years after the diagnosis.
The risk factors for developing adenocarcinoma are the duration and extent of disease. After the first decade of disease, the risk of development of colon cancer increases rapidly; thus, surveillance colonoscopy should be performed annually or biannually after 8-10 years of colonic disease. Colectomy should be performed if there is finding of dysplasia.[5]
The course of UC is marked by remissions and exacerbations. Most patients respond initially to medical treatment, and many children with mild manifestations stay in remission on prophylactic therapy with 5-aminosalicylic acid (5-ASA). Despite complications, most children with CD lead active lives, despite intermittent symptom flare-ups.
Patient Education
Psychosocial support and education for the family are important in achieving long-term goals in the treatment of IBD. Counseling and peer support for the adolescent who has growth and pubertal delays are helpful.
For patient education resources, see Crohn Disease in Children and Teens and Inflammatory Bowel Disease.
[Best Evidence] Henderson G, Craig S, Baier RJ, Helps N, Brocklehurst P, McGuire W. Cytokine gene polymorphisms in preterm infants with necrotising enterocolitis: genetic association study. Arch Dis Child Fetal Neonatal Ed. Mar 2009;94(2):F124-8. [Medline].
Higuchi LM. Epidemiology and diagnosis of inflammatory bowel disease in children and adolescents. UpToDate. 2005;12.3.
Hou JK, El-Serag H, Thirumurthi S. Distribution and Manifestations of Inflammatory Bowel Disease in Asians, Hispanics, and African Americans: A Systematic Review. Am J Gastroenterol. May 26 2009;[Medline].
Karwowski CA, Keljo D, Szigethy E. Strategies to improve quality of life in adolescents with inflammatory bowel disease. Inflamm Bowel Dis. May 26 2009;[Medline].
Watanabe C, Sumioka M, Hiramoto T, et al. Magnifying colonoscopy used to predict disease relapse in patients with quiescent ulcerative colitis. Inflamm Bowel Dis. Jun 5 2009;[Medline].
[Guideline] IBD Guideline Team, Cincinnati Children's Hospital Medical Center. Evidence-based care guideline for the management of pediatric moderate/severe inflammatory bowel disease (IBD). Apr 5 2007.
Hartman C, Eliakim R, Shamir R. Nutritional status and nutritional therapy in inflammatory bowel diseases. World J Gastroenterol. Jun 7 2009;15(21):2570-8. [Medline].
[Guideline] Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. Mar 2006;130(3):935-9. [Medline].
Floch MH, Madsen KK, Jenkins DJ, et al. Recommendations for probiotic use. J Clin Gastroenterol. Mar 2006;40(3):275-8. [Medline].
Eshuis EJ, Bemelman WA, Stokkers PC. Infliximab for the treatment of ulcerative colitis. Expert Rev Gastroenterol Hepatol. Jun 2009;3(3):219-29. [Medline].
Turner D, Mack D, Leleiko N, et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology. Feb 26 2010;[Medline].
Bousvaros A. Overview of the management of Crohn's disease in children and adolescents. UpToDate. 2005;13.2.
Hyams JS. Inflammatory bowel disease. Pediatr Rev. Sep 2005;26(9):314-20. [Medline].
Murray K. Ulcerative colitis in children and adolescents. UpToDate. 2005;13.2.
Komati JT, Sdepanian VL. Effectiveness of Infliximab in Brazilian Children and Adolescents With Crohn Disease and Ulcerative Colitis According to Clinical Manifestations, Activity Indices of Inflammatory Bowel Disease, and Corticosteroid Use. J Pediatr Gastroenterol Nutr. Apr 7 2010;[Medline].
[Best Evidence] Baldassarre ME, Laforgia N, Fanelli M, Laneve A, Grosso R, Lifschitz C. Lactobacillus GG improves recovery in infants with blood in the stools and presumptive allergic colitis compared with extensively hydrolyzed formula alone. J Pediatr. Mar 2010;156(3):397-401. [Medline].
Wiskin AE, Wootton SA, Culliford DJ, Afzal NA, Jackson AA, Beattie RM. Impact of disease activity on resting energy expenditure in children with inflammatory bowel disease. Clin Nutr. Jun 8 2009;[Medline].
Karoui S, Serghini M, Chaieb M, et al. [Frequency and predictive factors of colectomy and coloproctectomy in ulcerative colitis]. Tunis Med. Feb 2009;87(2):115-9. [Medline].
[Guideline] Cohen JL, Strong SA, Hyman NH, et al. Practice parameters for the surgical treatment of ulcerative colitis. Dis Colon Rectum. Nov 2005;48(11):1997-2009. [Medline].

